Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Gemcitabine/Fluorouracil and RT Variant #01 | — | R 11 569 | 77d | — | — | 3 | R 21 602 PFS proxy | 1 |
Capecitabine and Gemcitabine Variant #01 | — | R 6 309 | 21d | — | ~7.9 mo | ~6 | ~R 37 856 PFS proxy · indirect | 6 |
GemOx Variant #01 | — | R 2 937 | 14d | ~5.0 mo | ~9.0 mo | ~7 | ~R 20 560 PFS proxy · indirect | 5 |
Gemcitabine monotherapy Variant #01 | — | R 1 672 | 21d | ~4.7 mo | ~6.8 mo | ~7 | ~R 11 705 PFS proxy · indirect | 31 |
Capecitabine monotherapy Variant #01 | — | R 1 039 | 21d | ~5.7 mo | ~7.5 mo | ~2 | ~R 2 077 PFS proxy · indirect | 11 |
Capecitabine and RT Variant #01 | — | R 691 | 35d | — | — | ~1 | ~R 691 PFS proxy · indirect | 2 |
Observation Partial | — | — | — | ~3.4 mo | ~36.1 mo | — | — | 18 |
7 of 7 regimens shown